312620-93-2 Usage
Description
(S)-N-(4-(3,4-dichlorophenyl)-3,4-dihydronaphthalen-1(2H)-ylidene)methanamine, also known as (S)-4-(3,4-dichlorophenyl)-1,2,3,4-tetrahydronaphthalen-1-ylideneamine, is a chiral amine featuring a naphthalene ring structure. As a synthetic compound, it holds promise in the fields of pharmaceutical and medicinal chemistry due to its unique structural composition. (S)-N-(4-(3,4-dichlorophenyl)-3,4-dihydronaphthalen-1(2H)-ylidene)methanamine's potential biological or pharmacological properties make it a candidate for further research and development, with the aim of discovering new therapeutic agents. However, additional studies are necessary to comprehensively understand its applications and activities.
Uses
Used in Pharmaceutical Industry:
(S)-N-(4-(3,4-dichlorophenyl)-3,4-dihydronaphthalen-1(2H)-ylidene)methanamine is used as a potential therapeutic agent for its possible biological or pharmacological properties. Its unique structure may contribute to the development of new drugs, particularly in the treatment of various diseases and conditions.
Used in Medicinal Chemistry Research:
In the field of medicinal chemistry, (S)-N-(4-(3,4-dichlorophenyl)-3,4-dihydronaphthalen-1(2H)-ylidene)methanamine serves as a valuable compound for synthesis and characterization studies. These studies are crucial for understanding its potential applications and activities, which could lead to the creation of novel therapeutic agents and advancements in drug discovery.
Check Digit Verification of cas no
The CAS Registry Mumber 312620-93-2 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 3,1,2,6,2 and 0 respectively; the second part has 2 digits, 9 and 3 respectively.
Calculate Digit Verification of CAS Registry Number 312620-93:
(8*3)+(7*1)+(6*2)+(5*6)+(4*2)+(3*0)+(2*9)+(1*3)=102
102 % 10 = 2
So 312620-93-2 is a valid CAS Registry Number.
312620-93-2Relevant articles and documents
Chemoenzymatic Synthesis of Sertraline
Marx, Lisa,Ríos-Lombardía, Nicolás,Süss, Philipp,H?hne, Matthias,Morís, Francisco,González-Sabín, Javier,Berglund, Per
, p. 510 - 513 (2020/01/25)
A chemoenzymatic approach has been developed for the preparation of sertraline, an established anti-depressant drug. Ketoreductases (KREDs) were employed to yield a key chiral precursor. The bioreduction of the racemic tetralone exhibited excellent enantioselectivity (>99 % ee) and diastereomeric ratio (99:1) at 29 % conversion (the maximum theoretical yield is 50 %) after 7 hours. The resulting (S,S)-alcohol was efficiently oxidized to an enantiopure (S)-ketone, an immediate precursor of sertraline, by using sodium hypochlorite as oxidant and 2-azaadamantane N-oxyl (AZADO) as organocatalyst. Alternative routes aiming at the direct biocatalytic amination using imine reductases and transaminases were unsuccessful.
Asymmetric reduction of substituted indanones and tetralones catalyzed by chiral dendrimer and its application to the synthesis of (+)-sertraline
Wang, Guangyin,Zheng, Changwu,Zhao, Gang
, p. 2074 - 2081 (2007/10/03)
A recoverable dendrimeric supported prolinol was used as a catalyst in the asymmetric reduction of indanones and tetralones to give separable cis and trans isomers up to 97% ee. This method was also applied in the enantioselective synthesis of the antidepressant drug (+)-sertraline.
